{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Minimal response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Progression"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.","groups":[{"description":"Participants received 1.3 mg per m\\^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.","id":"OG000","title":"Bortezomib"}],"paramType":"NUMBER","populationDescription":"The FAS population included all the participants who received 1 dose of study medication and had post-dose efficacy data.","reportingStatus":"POSTED","timeFrame":"Day 11 of Cycle 8","title":"Number of Participants With Response to Treatment at Day 11 of Cycle 8","type":"PRIMARY","unitOfMeasure":"Participants"}